Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Total Valuation
Corvus Pharmaceuticals has a market cap or net worth of $412.81M. The enterprise value is $237.77M.
Market Cap$412.81M
Enterprise Value$237.77M
Share Statistics
Corvus Pharmaceuticals has 74,514,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding74,514,040
Owned by Insiders22.98%
Owned by Institutions27.32%
Financial Efficiency
Corvus Pharmaceuticals’s return on equity (ROE) is -1.91 and return on invested capital (ROIC) is -81.32%.
Return on Equity (ROE)-1.91
Return on Assets (ROA)-0.90
Return on Invested Capital (ROIC)-81.32%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee0.00
Profits Per Employee-2.01M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corvus Pharmaceuticals is ―. Corvus Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value10.02
Price to FCF―
Price to Operating Cash Flow-13.49
PEG Ratio―
Income Statement
In the last 12 months, Corvus Pharmaceuticals had revenue of 0.00 and earned -62.29M in profits. Earnings per share was -1.02.
Revenue0.00
Gross Profit-85.00K
Operating Income-27.55M
Pretax Income-62.29M
Net Income-62.29M
EBITDA-27.55M
Earnings Per Share (EPS)-1.02
Cash Flow
In the last 12 months, operating cash flow was -28.83M and capital expenditures -149.00K, giving a free cash flow of -28.98M billion.
Operating Cash Flow-28.83M
Free Cash Flow-28.98M
Free Cash Flow per Share-0.39
Dividends & Yields
Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.44
52-Week Price Change32.85%
50-Day Moving Average4.46
200-Day Moving Average4.88
Relative Strength Index (RSI)66.61
Average Volume (3m)479.21K
Important Dates
Corvus Pharmaceuticals upcoming earnings date is Oct 30, 2025, TBA (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Corvus Pharmaceuticals as a current ratio of 1.54, with Debt / Equity ratio of 1.35%
Current Ratio1.54
Quick Ratio1.54
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio-15.10
Taxes
In the past 12 months, Corvus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Corvus Pharmaceuticals EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -12.53.
EV to Sales0.00
EV to EBITDA-11.57
EV to Free Cash Flow-12.53
EV to Operating Cash Flow-12.53
Balance Sheet
Corvus Pharmaceuticals has $74.41M in cash and marketable securities with $1.08M in debt, giving a net cash position of -$73.32M billion.
Cash & Marketable Securities$74.41M
Total Debt$1.08M
Net Cash-$73.32M
Net Cash Per Share-$0.98
Tangible Book Value Per Share$0.53
Margins
Gross margin is -30.68%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-30.68%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corvus Pharmaceuticals is $12.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.33
Price Target Upside124.18% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-50.83%